论文信息 - Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial - 字舞流文

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial

S. Pinder | M. Wallis | D. Rea | L. Fallowfield | M. Reed | A. Evans | J. Bartlett | L. Billingham | M. Wilcox | D. Dodwell | C. Kirwan | A. Francis | C. Brookes | P. Fairbrother | A. Hanby | V. Jenkins | S. Bowden | C. Gaunt | T. Roberts | S. Pirrie | Jennie Young | L. Matthews | J. Thomas

[1] M. Morrow,et al. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma? , 2016, Annals of Surgical Oncology.

[2] S. Pinder,et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. , 2015, European journal of cancer.

[3] E. Rutgers,et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. , 2015, European journal of cancer.

[4] W. Han,et al. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. , 2012, Breast.

[5] E. Resetkova,et al. Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey. , 2010, Pathology, research and practice.

[6] N. Dallimore,et al. Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast , 2000, Journal of clinical pathology.

[7] A. Tosteson,et al. Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. , 2000, The American journal of surgical pathology.